Last €73.45 EUR
Change Today -0.008 / -0.01%
Volume 135.9K
MOR On Other Exchanges
Symbol
Exchange
Xetra
OTC US
OTC US
As of 3:35 PM 03/4/15 All times are local (Market data is delayed by at least 15 minutes).

morphosys ag (MOR) Snapshot

Open
€73.09
Previous Close
€73.46
Day High
€73.72
Day Low
€72.01
52 Week High
12/8/14 - €90.00
52 Week Low
04/15/14 - €53.70
Market Cap
1.9B
Average Volume 10 Days
122.9K
EPS TTM
€-0.12
Shares Outstanding
26.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for MORPHOSYS AG (MOR)

Related News

No related news articles were found.

morphosys ag (MOR) Related Businessweek News

No Related Businessweek News Found

morphosys ag (MOR) Details

MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies for therapeutic applications. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 80 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer’s disease. It operates therapeutic development programs for drug candidates in cooperation with various biotechnology and pharmaceutical companies, as well as focuses on the development of proprietary therapeutic antibodies. The company’s proprietary programs include MOR103, an antibody against GM-CSF for the treatment of rheumatoid arthritis and multiple sclerosis, as well as other proprietary clinical programs, including MOR202 and MOR208 for the treatment of cancer. It has strategic alliances with Novartis AG for the discovery and development of biopharmaceuticals; and Celgene Corporation for the development and co-promotion of the CD38 cancer program. The company was founded in 1992 and is headquartered in Martinsried, Germany.

Founded in 1992

morphosys ag (MOR) Top Compensated Officers

Chairman of Management Board and Chief Execut...
Total Annual Compensation: €751.2K
Chief Financial Officer and Member of Managem...
Total Annual Compensation: €509.6K
Chief Development Officer and Member of Manag...
Total Annual Compensation: €504.5K
Chief Scientific Officer and Member of Manage...
Total Annual Compensation: €499.5K
Compensation as of Fiscal Year 2014.

morphosys ag (MOR) Key Developments

Morphosys AG Reports Group Earnings Results for the Fourth Quarter and Year Ended December 31, 2014; Provides Group Earnings Guidance for the Year of 2015

Morphosys AG reported group earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, the company reported group revenues of EUR 14.4 million compared to EUR 17 million a year ago. LBIT was EUR 2.2 million compared to EUR 4.7 million a year ago. Loss from continuing operations was EUR 1.0 million compared to EUR 3.5 million a year ago. Net loss was EUR 1.0 million compared to EUR 3.5 million a year ago. For the year, the company reported group revenues of EUR 64 million compared to EUR 78 million a year ago. LBIT was EUR 5.9 million compared to EBIT of EUR 9.9 million a year ago. Loss from continuing operations was EUR 3.0 million compared to profit from continuing operations of EUR 7.4 million a year ago. Net loss was EUR 1.0 million or 0.12 per diluted share compared to net profit of EUR 13.3 million or 0.54 per diluted share a year ago. This decline resulted primarily from non-recurring effects in relation to the out-licensing of MOR103 to GlaxoSmithKline and license fees from the sale of the AbD Serotec business unit to Bio-Rad in 2013. Net cash outflow from operations in 2014 amounted to EUR 14.2 million compared to net cash inflow of EUR 89.1 million a year ago. The company expects group revenues for the 2015 financial year in the amount of EUR 58 million to EUR 63 million. The company expects loss before interest and taxes of approximately EUR 20 million to EUR 30 million in 2015.

Morphosys AG, 2014 Earnings Call, Feb 26, 2015

Morphosys AG, 2014 Earnings Call, Feb 26, 2015

Morphosys AG Presents at Leerink's Global Healthcare Conference, Feb-11-2015 03:05 PM

Morphosys AG Presents at Leerink's Global Healthcare Conference, Feb-11-2015 03:05 PM. Venue: Waldorf Astoria New York, New York, New York, United States. Speakers: Simon E. Moroney, Chairman of Management Board and Chief Executive Officer.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MOR:GR €73.45 EUR -0.008

MOR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Ablynx NV €9.55 EUR -0.001
BioInvent International AB kr2.39 SEK 0.00
Dyax Corp $15.67 USD +0.52
ImmunoGen Inc $7.73 USD +0.19
XOMA Corp $3.68 USD -0.05
View Industry Companies
 

Industry Analysis

MOR

Industry Average

Valuation MOR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 27.4x
Price/Book 5.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 25.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MORPHOSYS AG, please visit www.morphosys.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.